PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaFiona Collinson, Naveen Vasudev, Helen Howard et al.|Annals of Oncology|2018Cited by 2
Preoperative sodium concentration as a possible predictor of survival in patients with renal cell carcinomaNaveen Vasudev, Peter J. Selby, Janet E. Brown et al.|Journal of Clinical Oncology|2007Cited by 0